Parameters | n (%) | |
---|---|---|
Clinical and laboratory | Median age (years) (n= 511) | 58 years |
 < 60 | 287 (57.1) | |
 ≥ 60 | 216 (42.9) | |
Gender (n= 511) | ||
 Male | 428 (83.8) | |
 Female | 83 (16.2) | |
Etiology (n= 363) | ||
 HCV | 329 (90.6) | |
 HBV | 4 (1.1) | |
 Combined HCV/HBV | 2 (0.6) | |
 Non-viral | 28 (7.7) | |
Previous HCV treatment (n= 221) | ||
 IFN | 30 (13.6) | |
 DAAs | 123 (55.7) | |
 No | 68 (30.8) | |
Median AFP (n= 300) | 29 ng/dl | |
 AFP (≥ 20 ng/dl) | 180 (60) | |
 AFP (≥ 200 ng/dl) | 81 (27) | |
 AFP (≥ 400 ng/dl) | 52 (17.3) | |
Macroscopic | Tumor focality (n= 492) | |
 Solitary | 333 (67.7) | |
 Multiple | 159 (32.3) | |
Median tumor size (n= 480) | 5 cm | |
 Tumor size ≥ 2 cm | 430 (89.6) | |
 Tumor size ≥ 5 cm | 255 (53.1) | |
Microscopic | Pathological grade (n= 511) | |
 I | 34 (6.6) | |
 II | 357 (69.9) | |
 III | 82 (16) | |
 Un | 38 (7.5) | |
Pathological patterns of NOS (n= 375) | ||
 Trabecular and acinar | 341 (90.9) | |
 Solid | 34 (9.1) | |
Tumor clear and fatty cell changes (n= 511) | ||
 Absent | 288 (56.4) | |
 Present | 223 (43.6) | |
TILs Salgado classifications (n= 511) | ||
 0–10 | 459 (89.8) | |
 20–40 | 51 (10.0) | |
 50–90 | 1 (0.2) | |
Intra-tumoral fibrous stroma (n= 511) | ||
 Absent | 344 (67.3) | |
 Present | 167 (32.7) | |
Tumor necrosis (n= 511) | ||
 Negative | 360 (70.5) | |
 Positive | 151 (29.5) | |
Pathological stage (n= 368) | ||
 1a | 24 (6.5) | |
 1b | 121 (32.9) | |
 2 | 161 (43.8) | |
 3 | 49 (13.3) | |
 4 | 13 (3.5) | |
LVI (n= 372) | ||
 Negative | 201 (54.0) | |
 Positive | 171 (46.0) | |
Bile duct invasion (n= 368) | ||
 Negative | 365 (99.2) | |
 Positive | 3 (0.8) | |
Perineural invasion (n= 368) | ||
 Negative | 365 (99.2) | |
 Positive | 3 (0.8) | |
LN status (n= 39) | ||
 Negative | 29 (74.4) | |
 Positive | 10 (25.6) |